What's happening at Biomarx.

Press — The Irish News

6 January 2026

Belfast-based start-up secures £700,000 funding to transform lung cancer diagnostics

Biomarx has raised £700,000 in pre-seed funding to progress a diagnostics platform focused on lung cancer. Founded by Sean Macfarlane, the platform is intended to lower the technical and cost barriers associated with next-generation sequencing. The funds will take Biomarx from proof of concept to a minimum viable product, fund ISO 13485 accreditation, and support a preliminary lab-based clinical study.

Press — MedTech World

6 January 2026

Biomarx attracts £700,000 in pre-seed funding for lung cancer genomics

Biomarx's first test kit will target non-small cell lung cancer, one of the most commonly diagnosed cancers worldwide, using circulating tumour DNA to enable earlier detection and support more informed treatment stratification. The round was led by SFC Capital alongside Clarendon Fund Managers, with additional backing from the University of Strathclyde, Techstart Ventures and a group of angel investors.

Press — Business Post

5 January 2026

Belfast-based Biomarx secures funding to transform lung cancer diagnostics

As part of its next development phase, Biomarx will be based in Glasgow, working in collaboration with the University of Strathclyde to support product development and early-stage validation.

Press — Sync NI

5 January 2026

Medtech startup Biomarx raises £700k pre-seed to advance liquid biopsy diagnostics

"Cancer management is undergoing a major watershed moment, with greater focus on early detection, when outcomes are more favourable, alongside a transition away from one-size-fits-all chemotherapies and towards treatments targeting specific mutations. Here at Biomarx, we aim to join this movement, democratising more effective, more affordable and faster cancer care." — Sean Macfarlane, Founder.

Company

January 2026

Pre-Seed round closed — £700,000

Biomarx has closed its first ever investment round, led by SFC Capital and Clarendon Fund Managers, with additional support from the University of Strathclyde, our angel investors, the InterTradeIreland Seedcorn Competition and a Techstart Ventures Proof of Concept Plus grant. The funding takes Biomarx from proof of concept to MVP, funds ISO 13485 accreditation, and supports a preliminary lab-based clinical study.

Press — The Week In Irish Start Ups

January 2026

Biomarx featured in The Week In Irish Start Ups by Ed O'Riordan

Biomarx's pre-seed raise featured in Ed O'Riordan's weekly round-up of Irish start-up funding and company news.

Recognition

2025

InterTradeIreland Seedcorn DeepTech regional winner

Biomarx was named a regional winner in the DeepTech category of the InterTradeIreland Seedcorn competition, securing £50,000 in financing.

Partnership

Coming soon

University of Strathclyde partnership

Biomarx and the University of Strathclyde are partnering on a venture-capital-backed PhD programme, embedding Biomarx's development within world-class electrochemical biosensing research. Full release to follow.

Company

Ongoing

Seed Raise opening Q1 2027

Seed Raise opening Q1 2027. If you invest in early-stage diagnostics or deep-tech health, we'd like to talk.